LENSAR Inc (NASDAQ: LNSR) is a medical device company that develops and commercializes laser systems for cataract surgery. Revenue comes from three streams: product sales of the laser system and related consumables, procedure-based lease revenue tied to per-use fees, and service revenue from warranty and maintenance contracts. The company sells into ophthalmic surgical centers and practices, with performance obligations structured around the system hardware, patient interface devices (PIDs), procedure licenses, and extended warranty agreements. As of December 31, 2025, material contractual obligations included $2.7 million in operating lease liabilities and $13.9 million in remaining commitments. Net cash used in operating activities for the year ended December 31, 2024 was $2.3 million against a net loss of $31.4 million. A $10.3 million acquisition-related deposit was received from Alcon during the year ended December 31, 2025. The company manufactures its systems internally and sells primarily in the United States, with ongoing sales force growth noted in the FY2025 10-K.

Revenue model

Three-part revenue model: (1) product revenue from system and consumable sales, (2) lease revenue from per-procedure or equipment lease arrangements with depreciation-based cost structure, and (3) service revenue from standard limited warranties and extended warranty contracts. Multi-element contracts bundle the system, PID, procedure license, and extended warranty as distinct performance obligations.

Products and services

Laser cataract surgery systems with integrated cataract density imaging. Related consumables include patient interface devices (PIDs) and procedure licenses. Extended warranty and maintenance service contracts accompany system placements.

Customers and end markets

Ophthalmic surgical centers and cataract surgeons in the United States. End market is cataract surgery, where laser systems assist with precision incisions and lens fragmentation. Demand driven by surgeon adoption of laser-assisted cataract procedures.

Value-chain role

Medical device manufacturer and direct seller of laser cataract surgery platforms. Designs, manufactures, and services its own systems. Sells and leases directly to surgical facilities and ophthalmic practices.

Geographic exposure

Primary operations and sales in the United States, with international data transfer obligations under EU GDPR and UK GDPR indicating some international activity as of the FY2025 10-K filing.

Source: SEC 10-K, filed 2026-03-31

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Pulse Biosciences Inc Electromed Inc enVVeno Medical Corp Lucid Diagnostics Inc Neuronetics Inc Neuropace Inc PAVmed Inc